Business
Speedboat RS2 advances beyond initial pilot centre
Speedboat RS2 advances beyond initial pilot centre.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n \nRNS Number : 7877X Creo Medical Group PLC 29 November 2017 \n\nCreo Medical Group plc\n(\"Creo\" or \"the Company\")\n \nSpeedboat RS2 advances beyond initial pilot centre\n \nSpeedboat RS2 utilised at second NHS site\n \nChepstow, South Wales - 29 November 2017 - Creo Medical Group plc (AIM: CREO) is pleased to announce that Speedboat RS2 has been used by a second Gastroenterologist at a second NHS site to treat further patients. This follows the announcement earlier this year with the first patient being treated at St Marks hospital in London.\n \nInitial feedback from the first two cases at this site confirmed the removal of lesions under local anaesthetic with a procedure time of under one hour. The patients were discharged on the same day and are now under routine follow-up and monitoring. We await final histology results.\n \nCraig Gulliford, Chief Executive Officer of Creo Medical, commented: \"We are excited by today's announcement as it provides further validation of our technology. It is incredible that these patients were conscious, talking to the endoscopist and able to watch the procedure live on screen. While we need to collect additional supportive clinical data, we are encouraged by the results we've seen to date. We believe that procedures like this have the potential to eliminate the need for subsequent bowel surgery, with the obvious patient benefits aligned with material advantages to the healthcare system in terms of cost and patient safety.\"\n \n\n\n\n\nContacts \n\n\n\n\nCreo Medical: \n\n\nCenkos: \n\n\nFTI Consulting: \n\n\n\n\nRichard Rees \n+44 (0)1291 606005 [email protected] \n\n\nCamilla Hume / Mark Connelly (NOMAD) \nMichael Johnson / Russell Kerr (Sales) \n+44 (0)207 397 8900 \n\n\nBrett Pollard / Mo Noonan \n+44 (0)203 727 1000 \[email protected] \n\n\n\n\n \nAbout Creo Medical\n \nCreo Medical, founded in 2003, is a medical device company focused on improving patient outcomes by applying microwave and radiowave energy to a range of minimally invasive surgical devices. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency, for precise localised cutting, and microwaves, for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical s...